Graybug Vision, Inc.

( )
GRAY After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.50%163.450.7%$1076.37m
LLYEli Lilly & Co. 7.28%232.901.1%$1065.55m
MRKMerck & Co., Inc. 1.10%76.410.7%$1016.65m
PFEPfizer Inc. 0.44%39.220.9%$906.78m
ABBVAbbVie, Inc. 0.63%114.721.9%$728.45m
BMYBristol-Myers Squibb Co. 0.90%65.851.0%$622.40m
AZNAstraZeneca Plc 0.76%58.421.2%$386.40m
OGN 0.98%29.790.0%$259.48m
ORPHOrphazyme A/S 9.54%8.150.0%$248.32m
GSKGlaxoSmithKline Plc -0.33%39.720.2%$203.78m
NVSNovartis AG 0.07%92.450.2%$175.46m
CVACCureVac NV 5.01%59.760.0%$118.26m
CNSTConstellation Pharmaceuticals, Inc. 0.12%33.800.0%$111.49m
NOVNNovan, Inc. 1.91%10.695.8%$111.38m
RPRXRoyalty Pharma Plc 1.99%43.030.2%$109.39m

Company Profile

Graybug Vision, Inc. develops ophthalmic drugs. It focus on developing drug delivery therapies for the treatment of eye diseases such as age-related macular degeneration and glaucoma. The company was founded by Justin S. Hanes, Peter John McDonnell, Christy Wyskiel and Peter A. Campochiaro in May 2011 and is headquartered in Redwood City, CA.